Lantheus Holdings, Inc. Debt Instrument, Convertible, If-converted Value in Excess of Principal
Lantheus Holdings, Inc. (LNTH) reported Debt Instrument, Convertible, If-converted Value in Excess of Principal of $2.52 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes
us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal · last filed 2026-08-06
- 2026-06-30: Debt Instrument, Convertible, If-converted Value in Excess of Principal 6 month $2.52M.
- 2025-06-30: Debt Instrument, Convertible, If-converted Value in Excess of Principal 6 month $0.00.
| Period end | Debt Instrument, Convertible, If-converted Value in Excess of Principal 6 month |
|---|---|
| 2026-06-30 | $2.52M 10-Q · filed 2026-08-06 |
| 2025-06-30 | $0.00 10-Q · filed 2026-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B |